Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB

Table 2 Baseline and outcome characteristics of TB patients receiving placebo in combination with TB drugs for 30 days

No.	Sex	Age	Months on ATT prior to placebo	Dx	TB drugs regime	Smear status		Liver size in cm over normal		Erythrocyte sedimentation rate (mm/h)		Lymphocytes (%)		Leukocytes (× 10⁹/L)		Hemoglobin (g/L)		Body weight (kg)		Total bilirubin (μmol/L)		ALT (mM/h/ml)
						before	after	before	after	before	after	before	after	before	after	before	after	before	after	before	after	before	after
1	M	22	1	1^stDx	HRZSE	1	1	1	0	3	6	22	36	6.1	8.7	155	150	74	75	12.1	9.9	0.3	0.3
2	F	35	0	1^stDx	HRZSE	3	3	1	0	22	41	8	10	8	14.1	75	80	45	45	8.8	8.8	0.4	0.6
3	M	40	0	1^stDx	HRZSE	1	1	0	1	35	32	12	11	11.8	11.1	158	150	62	62	9.9	9.9	0.4	0.6
4	F	30	0	1^stDx	HRZSE	1	1	0	1	8	10	21	16	7.2	7.4	126	120	69	69	8.8	14	0.2	0.6
5	M	20	0	1^stDx	HRZSE	3	3	0	0	50	35	27	26	9.2	10.9	116	110	64	66	8.8	8.8	0.3	0.2
6	M	53	2	RTB	HRZSE	2	1	2	1	23	27	19	23	5.5	4.6	86	89	84	86	12.1	8.8	0.3	0.1
7	M	42	0	RTB	HRZSE	3	3	1	1	52	49	19	17	10	9.8	113	115	60	61	8.8	8.8	0.1	0.4
8	M	48	0	RTB	HRZSE	3	3	0	0	47	38	40	37	11	10.3	139	129	60	61	8.8	17.2	0.1	0.4
9	M	22	1	MDR	HRZSE	1	1	1	1	31	20	17	13	8.8	7.7	136	146	70	72	8.8	8.8	0.4	0.6
10	M	36	1	MDR	ZAPPtO	1	1	3	3	33	30	27	25	10.1	9.1	107	131	69	69	21	12.1	0.7	1.7
	2/8	Mean = 34.8 ± 3.58 Median = 35.5	Mean = 0.5 ± 0.7 Median = 0			1.9	1.8	0.9 ± 0.31	0.8 ± 0.29	30.4 ± 5.30	28.8 ± 4.27	21.2 ± 8.9	21.4 ± 9.7	8.77 ± 0.65	9.37 ± 0.80	121.1 ± 8.64	122 ± 7.69	65.7 ± 3.25	66.6 ± 3.39	10.79 ± 1.21	10.71 ± 0.90	0.32 ± 0.05	0.55 ± 0.14
						P = 0.34		P = 0.68		P = 0.61		P = 0.91		P = 0.43		P = 0.79		P = 0.01		P = 0.96		P = 0.055

TB drugs used in this arm are abbreviated as follows: Izoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E), Streptomycin (S), Amikacin (A), Para-aminosalicylic acid (P), Prothionamide (Pt), Ofloxacin (O)